Evidence map›Paper›PMID 29482223›Full record

ArticleJAMA neurology2018

Efficacy of Exome-Targeted Capture Sequencing to Detect Mutations in Known Cerebellar Ataxia Genes.

Marie Coutelier, Monia B Hammer, Giovanni Stevanin, Marie-Lorraine Monin, Claire-Sophie Davoine, Fanny Mochel, Pierre Labauge, Claire Ewenczyk, Jinhui Ding, J Raphael Gibbs and 26 more

Open access · bronzeAbstract read
In one paragraph

Article in JAMA neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 2 pooled it
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 2 syntheses or guidelines pooled it, 123 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. International journal of molecular sciences · 2026
    Article
  4. Article
  5. Expanding theNeurology. Genetics · 2026
    Article
  6. Article
  7. Novel homozygousTherapeutic advances in neurological disorders · 2026
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Understanding coenzyme Q.Physiological reviews · 2024
    Review
  16. Article
  17. Review
  18. Genetic aspects of ataxias in a cohort of Turkish patients.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Article
  19. Article
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors at 17 institutions in 4 countries.

Marie CoutelierInstitut National de la Santé et de la Recherche Medicale (INSERM) U1127, Paris, France.
Monia B HammerLaboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland.
Giovanni StevaninInstitut National de la Santé et de la Recherche Medicale (INSERM) U1127, Paris, France.
Marie-Lorraine MoninCentre de Référence de Neurogénétique, Hôpital de la Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Claire-Sophie DavoineInstitut National de la Santé et de la Recherche Medicale (INSERM) U1127, Paris, France.
Fanny MochelInstitut National de la Santé et de la Recherche Medicale (INSERM) U1127, Paris, France.
Pierre LabaugeService de Neurologie, Hopital Gui de Chauliac, Centre Hospitalier Universitaire (CHU) de Montpellier, Montpellier, France.
Claire EwenczykCentre de Référence de Neurogénétique, Hôpital de la Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Jinhui DingLaboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland.
J Raphael GibbsLaboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland.
Didier HannequinService de Génétique, Service de Neurologie, INSERM U1079, Rouen University Hospital, Rouen, France.
Judith MelkiUMR 1169, INSERM and University Paris Saclay, Le Kremlin Bicêtre, France.
Annick ToutainService de Génétique, Centre Hospitalier Universitaire de Tours, INSERM U930, Faculté de Médecine, Université François Rabelais, Tours, France.
Vincent LaugelService de Pédiatrie 1, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Sylvie ForlaniInstitut National de la Santé et de la Recherche Medicale (INSERM) U1127, Paris, France.
Perrine CharlesCentre de Référence de Neurogénétique, Hôpital de la Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Emmanuel BroussolleService de Neurologie C, Hôpital Neurologique Pierre-Wertheimer, Hospices Civils de Lyon, Bron, France.
Stéphane ThoboisService de Neurologie C, Hôpital Neurologique Pierre-Wertheimer, Hospices Civils de Lyon, Bron, France.
Alexandra AfenjarService de Génétique et Centre de Référence Pour les Malformations et les Maladies Congénitales du Cervelet, AP-HP, Paris, France.
Mathieu AnheimFédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg, France.
Patrick CalvasService de Génétique Médicale, CHU de Toulouse, Hôpital Purpan, Toulouse, France.
Giovanni CastelnovoService de Neurologie, CHU Caremeau, Nîmes, France.
Thomas de BrouckerService de Neurologie, Centre Hospitalier de Saint-Denis, Saint-Denis, France.
Marie VidailhetInstitut National de la Santé et de la Recherche Medicale (INSERM) U1127, Paris, France.
Antoine MoulignierService de Neurologie, Fondation Ophtalmologique A. de Rothschild, Paris, France.
Robert T Ghnassiaprivate practice, Chelles, France.
Chantal TallaksenInstitut National de la Santé et de la Recherche Medicale (INSERM) U1127, Paris, France.
Cyril MignotDépartement de Génétique and Centre de Référence Déficiences Intellectuelles de Causes Rares, Groupe Hospitalier Pitié Salpêtrière, AP-HP, Paris, France.
Cyril GoizetLaboratoire Maladies Rares, Génétique et Métabolisme, Université de Bordeaux, Bordeaux, France.
Isabelle Le BerInstitut National de la Santé et de la Recherche Medicale (INSERM) U1127, Paris, France.
Elisabeth Ollagnon-RomanService de Neurogénétique, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.
Jean PougetCentre de Référence des Maladies Neuromusculaires et de la Sclérose Latérale Amyotrophique, Assistance Publique-Hôpitaux de Marseille, Aix Marseille Université, Hôpital de La Timone, Marseille, France.
Alexis BriceInstitut National de la Santé et de la Recherche Medicale (INSERM) U1127, Paris, France.
Andrew SingletonLaboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland.
Alexandra DurrInstitut National de la Santé et de la Recherche Medicale (INSERM) U1127, Paris, France.
Spastic Paraplegia and Ataxia Network
Inserm · FRNational Institutes of Health · USSorbonne Université · FRUniversité Claude Bernard Lyon 1 · FRAix-Marseille Université · FRAssistance Publique – Hôpitaux de Paris · FRCentre Hospitalier Saint-Denis · FRCentre Hospitalier Universitaire de Nîmes · FRCentre Hospitalier Universitaire de Toulouse · FRCentre National de la Recherche Scientifique · FRFondation Ophtalmologique Adolphe de Rothschild · FRHôpital de la Croix-Rousse · FRHôpital Gui de Chauliac · FRHôpitaux Universitaires de Strasbourg · FROslo University Hospital · NOUniversité de Bordeaux · FRUniversité de Tours · FR

Funding

Assessment of Candidate Loci in Neurological diseasesZIAAG000957 · NIA · NATIONAL INSTITUTE ON AGING · PI SINGLETON, ANDREW · 2009 to 2024
$12.2M
Genetic analysis in families with neurological diseaseZIAAG000958 · NIA · NATIONAL INSTITUTE ON AGING · PI SINGLETON, ANDREW · 2009 to 2024
$10.9M
Whole Genome Screen in families with Parkinson's diseaseZ01AG000958 · NIA · NATIONAL INSTITUTE ON AGING · PI SINGLETON, ANDREW B · 2003 to 2008
$1.4M
Intramural NIH HHS Z99 AG999999NIA NIH HHS Z01 AG000958
6 · The paper itself

Abstract

Importance: Molecular diagnosis is difficult to achieve in disease groups with a highly heterogeneous genetic background, such as cerebellar ataxia (CA). In many patients, candidate gene sequencing or focused resequencing arrays do not allow investigators to reach a genetic conclusion. Objectives: To assess the efficacy of exome-targeted capture sequencing to detect mutations in genes broadly linked to CA in a large cohort of undiagnosed patients and to investigate their prevalence. Design, Setting, and Participants: Three hundred nineteen index patients with CA and without a history of dominant transmission were included in the this cohort study by the Spastic Paraplegia and Ataxia Network. Centralized storage was in the DNA and cell bank of the Brain and Spine Institute, Salpetriere Hospital, Paris, France. Patients were classified into 6 clinical groups, with the largest being those with spastic ataxia (ie, CA with pyramidal signs [n = 100]). Sequencing was performed from January 1, 2014, through December 31, 2016. Detected variants were classified as very probably or definitely causative, possibly causative, or of unknown significance based on genetic evidence and genotype-phenotype considerations. Main Outcomes and Measures: Identification of variants in genes broadly linked to CA, classified in pathogenicity groups. Results: The 319 included patients had equal sex distribution (160 female [50.2%] and 159 male patients [49.8%]; mean [SD] age at onset, 27.9 [18.6] years). The age at onset was younger than 25 years for 131 of 298 patients (44.0%) with complete clinical information. Consanguinity was present in 101 of 298 (33.9%). Very probable or definite diagnoses were achieved for 72 patients (22.6%), with an additional 19 (6.0%) harboring possibly pathogenic variants. The most frequently mutated genes were SPG7 (n = 14), SACS (n = 8), SETX (n = 7), SYNE1 (n = 6), and CACNA1A (n = 6). The highest diagnostic rate was obtained for patients with an autosomal recessive CA with oculomotor apraxia-like phenotype (6 of 17 [35.3%]) or spastic ataxia (35 of 100 [35.0%]) and patients with onset before 25 years of age (41 of 131 [31.3%]). Peculiar phenotypes were reported for patients carrying KCND3 or ERCC5 variants. Conclusions and Relevance: Exome capture followed by targeted analysis allows the molecular diagnosis in patients with highly heterogeneous mendelian disorders, such as CA, without prior assumption of the inheritance mode or causative gene. Being commonly available without specific design need, this procedure allows testing of a broader range of genes, consequently describing less classic phenotype-genotype correlations, and post hoc reanalysis of data as new genes are implicated in the disease.

Indexed as

Genetic Predisposition to DiseaseAdolescentAdultATPases Associated with Diverse Cellular ActivitiesCalcium ChannelsCalcium Channels, N-TypeCerebellar AtaxiaCohort StudiesComputational BiologyCytoskeletal ProteinsDNA HelicasesExome SequencingFemaleHeat-Shock ProteinsHumansMaleATPases Associated with Diverse Cellular ActivitiesCACNA1A protein, humanCalcium ChannelsCalcium Channels, N-TypeCytoskeletal ProteinsDNA HelicasesHeat-Shock ProteinsMetalloendopeptidasesMultifunctional EnzymesNerve Tissue ProteinsNuclear ProteinsRNA HelicasesSACS protein, humanSETX protein, humanSPG7 protein, humanSYNE1 protein, human

Identifiers

PMID29482223
PMCPMC5885259
OpenAlexW2790232193

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.